The Pharma Data

JANUARY 4, 2021

. Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

Drug Discovery World

SEPTEMBER 6, 2022

This will be driven in a major way through breadth of ongoing research and an increased move to better tolerated, logistically simpler allogeneic platforms, such as the optimized Natural Killer (NK) cell therapies being developed at ONK Therapeutics. Chris Nowers, CEO, ONK Therapeutics. . “ Víctor Cervera-Carrascón, Tilt Bio. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. This partnership will expand the company’s immunology pipeline.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

FEBRUARY 16, 2023

Additional solutions include compression and friability testers, spectrophotometers, digital multimeters (DMMs), field measuring equipment, recorders, data loggers, resistance meters, power meters, signal generators, calibrators, probes, sensors, precision balances, and grips and fixtures.

Engineer 130

Engineer Manufacturing Containment Production 130